Vanderbilt TB Center News

Dr. Dooley’s TB research receives MERIT Award from the NIH

Kelly Dooley, MD, PhD, MPH, Addison B. Scoville Jr. Professor of Medicine and director of the Division of Infectious Diseases at Vanderbilt University Medical Center, has received a MERIT Award (Method to Extend Research in Time Award) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

NIH Awards UM1 Funding to Establish PReDicTR Consortium

Rada Savic, PhD and colleagues Eric Nuermberger, MD (JHU), Kelly Dooley, MD, PhD, MPH (Vanderbilt), and Dirk Schnappinger, PhD (WCM) have been awarded a five-year $30.8M, UM1 cooperative agreement award from NIAID/NIH to establish a consortium of tuberculosis preclinical and clinical experts to research the most effective treatment options for future clinical testing, called the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium. PReDicTR will establish a mu

Successful Semi Annual Meeting of RePORT-Brazil

The Regional Prospective Observational Research for Tuberculosis (RePORT) - Brazil Semi Annual Meeting was held October 17th through October 21st in Salvador, Bahia. Investigators and staff from throughout the network participated in a variety of workshops, presentations, and collaborative planning sessions, both in-person and from remote locations. 

VUMC lands Grant to build top-line Biosafety Facility

Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. When the renovation of about 3,500 square feet of existing space is completed, the facility will include three BSL3 suites with separate entrances and seven procedure rooms capable of securely containing multiple organisms at the second-highest biosafety level.

Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.